Janssen’s CAR T-cell therapy, JNJ-68284528, for multiple myeloma is one of three new investigational products that have secured a place on the European Medicines Agency’s priority medicines (PRIME) scheme for getting drugs for unmet medical needs through the review process and to patients faster.
The PRIME designation for Janssen's B-cell maturation antigen (BCMA) CAR T-therapy is expected to help the company keep pace with...







